Notícias Eulerpool Syndax Pharmaceuticals

Syndax Pharmaceuticals Notícias de ações

Syndax Pharmaceuticals é observado por muitos jornalistas e investidores em todo o mundo. As notícias mais recentes de Syndax Pharmaceuticals nós reunimos aqui.

• 9 de dezembro ·

  Yahoo
  Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
• 8 de dezembro ·

  Yahoo
  Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
• 4 de dezembro ·

  Yahoo
  Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
• 27 de novembro ·

  Yahoo
  Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
• 18 de novembro ·

  Yahoo
  Syndax secures FDA OK for new kind of leukemia drug
• 18 de novembro ·

  Yahoo
  FDA approves Syndax’s Revuforj to treat leukaemia
• 15 de novembro ·

  Yahoo
  Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
• 14 de novembro ·

  Yahoo
  Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
• 13 de novembro ·

  Yahoo
  Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint
• 13 de novembro ·

  Yahoo
  Syndax’s revumenib meets primary results in AML trial